Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [single-cell RNA-seq]

ABSTRACT: The on/off dynamics of IFNβ signalling underlie the therapeutic response to immune checkpoint therapy in cancer, which can be identified in Ly6C+ monocytes

ORGANISM(S): Mus musculus

PROVIDER: GSE153942 | GEO | 2022/06/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [bulk RNA-seq]

Project description:The on/off dynamics of IFNβ signalling underlie the therapeutic response to immune checkpoint therapy in cancer, which can be exploited to sway the clinical trajectory in favour of response

2020-12-07 | GSE153941 | GEO

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer

Project description:Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer

| PRJNA644586 | ENA

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [bulk RNA-seq]

Project description:Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [bulk RNA-seq]

| PRJNA644589 | ENA

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-12-07 | GSE153943 | GEO

Time-course bulk RNAseq and single-cell RNAseq of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

Project description:The on/off dynamics of IFNβ signalling underlie the therapeutic response to immune checkpoint therapy in cancer in mice

2022-09-14 | GSE213296 | GEO

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.

Project description:The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the inability to frequently sample tumours in patients. Here, we map the transcriptional profiles of 144 responding and non-responding tumours within two mouse models at four time points during ICB. We find that responding tumours display on/fast-off kinetics of type-I-interferon (IFN) signaling. Phenocopying of this kinetics using time-dependent sequential dosing of recombinant IFNs and neutralizing antibodies markedly improves ICB efficacy, but only when IFNβ is targeted, not IFNα. We identify Ly6C+/CD11b+ inflammatory monocytes as the primary source of IFNβ and find that active type-I-IFN signaling in tumour-infiltrating inflammatory monocytes is associated with T cell expansion in patients treated with ICB. Together, our results suggest that on/fast-off modulation of IFNβ signaling is critical to the therapeutic response to ICB, which can be exploited to drive clinical outcomes towards response.

| S-EPMC9390963 | biostudies-literature

IFNβ expression is restricted to a subpopulation of splenic pDCs exhibiting a specific immune modulatory transcriptome signature

Project description:Type I IFNs are critical in initiating protective antiviral immune responses and plasmacytoid DCs (pDCs) represent a major source of these cytokines. Here we show that only few pDCs are capable to produce IFNβ after virus infection or CpG stimulation. Utilizing IFNβ/YFP reporter mice, we identify these IFNβ-producing cells in the spleen as a CCR9+CD9- pDC subset exclusively localized within the T/B cell zones. IFNβ-producing pDCs exhibit a distinct transcriptome profile with higher expression of genes encoding cytokines and chemokines, facilitating T cell recruitment and activation. These distinctive characteristics of IFNβ-producing pDCs are independent of the type I IFN receptor mediated feedback loop. Furthermore, IFNβ-producing pDCs exhibit enhanced CCR7-dependent migratory properties in vitro and in a peritoneal inflammation model they effectively recruit T cells in vivo. We define “professional type I IFN-producing cells” as a distinct subset of pDCs specialized in coordinating cellular immune responses.

2015-05-27 | GSE68788 | GEO

Microarray data of human moDC treated with IFNβ and TNFα

Project description:Human moDC were treated with IFNβ and TNFα or the combination of both for either 1 h or 2.5 h in triplicate and profiled by gene expression microarray

2020-11-30 | GSE134209 | GEO

Effects of the treatment with IFNβ and GM-CSF-secreting CT2A cells to wildtype CT2A tumor microenvironment post resection

Project description:To elucidate the underlying immune responses elicited by IFNβ and GM-CSF-secreting CT2A cells to brain tumor microenvironment post resection compared to placebo group and non-IFNβ and GM-CSF-secreting CT2A cell group

2022-11-09 | GSE217253 | GEO

dsRNA induced IFNβ-MMP13 axis drives corneal wound healing

Project description:dsRNA induced IFNβ-MMP13 axis drives corneal wound healing

| PRJNA790630 | ENA